CDKN2A and metastatic melanoma: In contrast, the SMGs in both cytolytic subgroups of metastatic melanomas included previously described [34] driver mutations in oncogenes (NRAS, BRAF and CDKN2A) and tumor suppressors (TP53 and PTEN), as well as COL4A4.